Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Oct 26 2024 48 ep. 26 mins 9

Talking About Tumors with Ryann and Ryan - A medical oncology podcast artwork

Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer

Education Health & Fitness Science

Copy RSS

Subscribe on Podcast Addict

04_10 Testicular Cancer II

Oct 26 2024 25 mins

1. Stage II Disease2. Overview of BEP, EP, VIP3. Advanced, refractory disease4. Survivorship considerationsCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr.,

04_09 Testicular Cancer I

Sep 17 2024 28 mins

1. Background, work up2. Staging of seminoma and NSGCT3. Young Adult/Adolescent Oncology4. Management of Stage I Disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vin

04_08 Metastatic Renal Cell Carcinoma

Aug 02 2024 24 mins

1. Historical Approach (cytoreduction, IFN-a, sunitinib2. Prognostic risk scores3. Evidence for modern doublet regimens4. Later line therapyCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your pr

04_07 Localized Renal Cell Carcinoma

Jul 06 2024 25 mins

1. Risk Factors and Presentation2. Staging and Paraneoplastic syndromes3. Localized Therapy Options and Considerations4. Evidence and Limitations for Adjuvant Systemic Therapy CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and

04_06 Metastatic Urothelial Cancer

May 23 2024 24 mins

1. Immunohistochemistry of urothelial cancer2. History of systemic therapy in advanced and metastatic disease3. Pembrolizumab and Enfortumab Vedotin4. Approach to second line therapy and beyondCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published b

04_05 Muscle Invasive Bladder Cancer

Apr 20 2024 29 mins

1. Etymology, presentation, and work-up of bladder/urothelial cancer2. Role of perioperative systemic therapy3. Tri-modality therapy (bladder sparing approach)4. Considerations for upper tract urothelial cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guid

01_14 Ampullary Carcinoma (Mini Discussion)

Apr 10 2024 10 mins

1. Clinical presentation and work-up2. Intestinal and pancreatobiliary subtypes3. Role of perioperative therapy4. Considerations for metastatic diseaseCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local

04_04 Castrate Resistant Metastatic Prostate Cancer

Feb 21 2024 24 mins

1. On continuation of ADT and ARAT switch2. Systemic therapy options after progression3. Improper mandated crossover4. PARP inhibitors in prostate cancerCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations loc

04_03 Metastatic Castrate Sensitive Prostate Cancer

Feb 04 2024 29 mins

1. The chemotherapy revolution in prostate cancer2. Role of ARATs in earlier disease states3. Triple therapy (chemotherapy, ADT, and ARAT)4. Considerations for frailer patients with indolent disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publi

04_02 Adjuvant Options for Prostate Cancer

Jan 07 2024 28 mins

1. Physiology, efficacy and toxicities of androgen deprivation2. Evidence for adjuvant intervention after definitive surgery or radiation3. Role of abiraterone in high-risk localized prostate cancer4. Limited evidence to support definitive salvage approachCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Upt